US OptionsDetailed Quotes
IBB240628P119000
- 0.05
- 0.000.00%
15min DelayClose Jun 28 15:49 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume29 Open Interest119.00Strike Price0.00Turnover1092.21%IV13.34%PremiumJun 28, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0150Delta0.0041Gamma2745.20Leverage Ratio-11.5817Theta0.0000Rho-41.27Eff Leverage0.0003Vega
iShares Biotechnology ETF Stock Discussion
Buy this ETF before the biotechnology boom will come next time
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer(PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences(GILD.US)$ 's $4.3 b...
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF(TLT.US)$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
Big Pharma’s patent cliff issue getting mainstream media attention,
Top 20 biopharma have $180 bil in sales at risk from patent expirations by 2028 according to EY,
But that estimate could prove low compared to…👇
Bloomberg Intelligence business estimates 170 drugs w/ close to $400 bil in est global sales could lose patent excl by start of next decade,
Big Pharma wants to avoid stagnant rev g...
moomoo.com/cour...
1. Record cash for big pharma 💰
2. Patent cliff for big pharma
3. Interest rate cuts ✂️
4. Many stocks still trading near cash
5. Best ever tech in biotech 🧬 🤖
6. Investors with big gains will look for value in the market
7. Tons of cash on the sidelines in money market and CD’s 💵
8. Technology like CRISPR starting to have hundreds dosed each year (more trials, more diseases, more durability)
9. Many of the biotechs with rev...
S&P Surges 2%+ after Lower Inflation Sparks Buying Frenzy
U.S. stocks opened sharply Tuesday after the October CPI numbers showed inflation had slowed to the slowest growth since Sept 2021. The numbers reinforced expectations the Federal Reserve is finished raising interest rates, and investors continued to pencil in rate cuts in 2024. The CME Fed rate change probability tool briefly tracked a 0% chance of a rate ...
No comment yet